CMI published a business research report on “Ebola Vaccine Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2021–2027”. Ebola Vaccine with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.
Ebola Vaccine Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Ebola Vaccine Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Get Your FREE Sample Copy of the Ebola Vaccine Market Report 2021
Ebola virus disease is one of the most deadly diseases and it affects human and nonhuman primates. It is a life-threatening disease caused by direct contact with the body fluid of an infected person. Fever, vomiting, sore throat, headache, diarrhea, and body pain are some of the most common symptoms of Ebola virus disease. There is no cure for Ebola virus disease however, the symptom can be controlled by maintaining electrolyte balance, imagining required oxygen level, and treating the infection. The vaccines to prevent Ebola virus disease are under development stage.
Rising cases of Ebola disease and growing initiatives for the development of vaccines are projected to fuel the market growth
Rising mortality rates due to Ebola is the prime factor fueling market growth. According to the World Health Organization, in January 2018, around 50% of people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, an outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during the 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected
African countries and people who came in contact with infected patients. In May 2017, the WHO declared an outbreak of EVD in the Democratic Republic of Congo. There is still fear about the potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure. Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD. According to a study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company were found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV uses a strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3, 00,000 vaccines, in case of a fresh outbreak in vulnerable regions. Several key manufacturers are focusing on producing vaccines for EVD, in order to expand its market presence. For instance, GlaxoSmithKline developed the CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by the National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed the Ebola vaccine by using its proprietary recombinant technology.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1365
Reasons to Purchase this Report
• Current and future of global Ebola Vaccine market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1365
Market Segmentation
By virus strain, the global Ebola vaccine market is segmented into:
- Recombinant vesicular stomatitis virus-Zaire Ebola virus
- Chimpanzee Adeno virus type 3-Zaire Ebola virus
- Adeno virus serotype 26- Zaire Ebola Virus
In January 2018, GeoVax Labs Inc. published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus-like Particle (VLP) platform, which produces non-infectious VLPs in the body of the vaccinated individuals.
This VLP mimics the natural infection, which triggers the body to produce an immune response with both antibodies and T cells.GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine). Major players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc.
Main points in Ebola Vaccine Market Report Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Ebola Vaccine Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Ebola Vaccine Industry Impact
Chapter 2 Global Ebola Vaccine Competition by Types, Applications, and Top Regions and Countries
2.1 Global Ebola Vaccine (Volume and Value) by Type
2.3 Global Ebola Vaccine (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Ebola Vaccine Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Ebola Vaccine Market Analysis
Chapter 6 East Asia Ebola Vaccine Market Analysis
Chapter 7 Europe Ebola Vaccine Market Analysis
Chapter 8 South Asia Ebola Vaccine Market Analysis
Chapter 9 Southeast Asia Ebola Vaccine Market Analysis
Chapter 10 Middle East Ebola Vaccine Market Analysis
Chapter 11 Africa Ebola Vaccine Market Analysis
Chapter 12 Oceania Ebola Vaccine Market Analysis
Chapter 13 South America Ebola Vaccine Market Analysis
Chapter 14 Company Profiles and Key Figures in Ebola Vaccine Business
Chapter 15 Global Ebola Vaccine Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Request for Analysis of COVID-19 Impact on Ebola Vaccine Market – https://www.coherentmarketinsights.com/insight/request-sample/1365
Major Point Answered in Ebola Vaccine Market Research Study are: –
• What will the market growth rate, Overview and Analysis by Type of Ebola Vaccine market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Ebola Vaccine market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Ebola Vaccine market?
• Who are Opportunities, Risk and Driving Force of Ebola Vaccine market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in Ebola Vaccine market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Ebola Vaccine market opportunities and threats faced by the vendors in the market?
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837